PMS2 amplification contributes brain metastasis from lung cancer

Authors: Jianing Chen, Congli Hu, Hainan Yang, Li Wang, Xiangling Chu, Xin Yu, Shiji Zhang, Xuefei Li, Chao Zhao, Lei Cheng, Weiping Hong, Da Liu, Lei Wen, Chunxia Su

Source: Biological Procedures Online, Vol 26, Iss 1, Pp 1-10 (2024)

Subject Terms: Lung cancer, Brain metastasis, PMS2, Medicine (General), R5-920, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://doaj.org/toc/1480-9222

Access URL: https://doaj.org/article/fef7bec84d0b4a6e95cefd470a150305

A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Authors: Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su

Source: Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)

Subject Terms: efficacy, first‐line treatment, HER2‐mutant, lung adenocarcinoma, pyrotinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/6c95b3d25dbb4a69a74abb4db48d898d

DNMT3A-mediated DNA methylation and transcription inhibition of FZD5 suppresses lung carcinogenesis

Authors: Jiqiao Shen, Jinchen Su, Xiangling Chu, Xin Yu, Xiwen Gao

Source: Heliyon, Vol 10, Iss 9, Pp e29733- (2024)

Subject Terms: Urethane, NSCLC, FZD5, DNMT3A, Science (General), Q1-390, Social sciences (General), H1-99

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405844024057645; https://doaj.org/toc/2405-8440

Access URL: https://doaj.org/article/30bb044717a14e14a1c151155bade8f4

Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy

Authors: Li Wang, Xiangling Chu, Xin Yu, Chunxia Su

Source: Heliyon, Vol 10, Iss 7, Pp e27801- (2024)

Subject Terms: NSCLC, Immune checkpoint inhibitors, Nomogram, cBioPortal, Science (General), Q1-390, Social sciences (General), H1-99

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405844024038325; https://doaj.org/toc/2405-8440

Access URL: https://doaj.org/article/fa6662063d484fd6aaeed5d722ad719c

Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

Authors: Juan Zhou, Xiangling Chu, Jing Zhao, Mengqing Xie, Jing Wu, Xin Yu, Yujia Fang, Yazhou Li, Xiyan Li, Chunxia Su

Source: Biological Procedures Online, Vol 25, Iss 1, Pp 1-13 (2023)

Subject Terms: Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance, Immune checkpoint inhibitor (ICI) plus chemotherapy, Peripheral blood mononuclear cell (PBMC), Medicine (General), R5-920, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://doaj.org/toc/1480-9222

Access URL: https://doaj.org/article/67c780f444bc46258dd9398bbbe65e60

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Authors: Mengqing Xie, Xin Yu, Xiangling Chu, Huikang Xie, Juan Zhou, Jing Zhao, Chunxia Su

Source: Thoracic Cancer, Vol 13, Iss 3, Pp 353-360 (2022)

Subject Terms: biomarker, immune checkpoint inhibitors (ICIs), non‐small cell lung cancer (NSCLC), proprotein convertase subtilisin/kexin type 9 (PCSK9), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/81596293e4ea4521be8918086166d5e2

Total reward satisfaction profiles and work performance: A person-centered approach

Authors: Chunling Li, Xueyun Duan, Xiangling Chu, Yong Qiu

Source: Heliyon, Vol 9, Iss 3, Pp e14154- (2023)

Subject Terms: A person-centered approach, Latent profile analysis (LPA), Total reward satisfaction (TRS), Work performance, Science (General), Q1-390, Social sciences (General), H1-99

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405844023013610; https://doaj.org/toc/2405-8440

Access URL: https://doaj.org/article/29403e85710c466692c63a40e39b41a9

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors

Authors: Jianing Chen, Yaokai Wen, Xiangling Chu, Yuzhi Liu, Chunxia Su

Source: Frontiers in Pharmacology, Vol 13 (2022)

Subject Terms: pharmacovigilance, immune checkpoint inhibitor, hypertension, NSCLC, FAERS, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.944342/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/b0d9c54c184c49a89678a3236c0bfe94

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure

Authors: Juan Zhou, Chao Zhao, Jing Zhao, Qi Wang, Xiangling Chu, Jiayu Li, Fei Zhou, Shengxiang Ren, Xuefei Li, Chunxia Su, Caicun Zhou

Source: Thoracic Cancer, Vol 10, Iss 4, Pp 957-965 (2019)

Subject Terms: EGFR‐TKI resistance, liquid biopsy, non‐small cell lung cancer, re‐biopsy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/77fa4fcccfa840218b5472b06e41d1c8

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer

Authors: Juan Zhou, Jing Zhao, Qingzhu Jia, Qian Chu, Fei Zhou, Xiangling Chu, Wencheng Zhao, Shengxiang Ren, Caicun Zhou, Chunxia Su

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: biomarker, autoantibody, tumor-associated antigen, immune checkpoint inhibitor, lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.625578/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/af9915f12a2a4aeda5dc8f7efcb17fcd